Chasing Hope MBC is working to overcome obstacles for funding Ibrance for Metastatic Breast Cancer. You can help today by signing their petition!
Ibrance (Palbociclib) is a treatment for Metastatic Breast Cancer made by the Pfizer drug company. It’s the first drug of its kind and the first drug in 10 years that has been introduced to fight MBC. This targeted treatment is designed for ER+ PR+ HER2-negative patients and is consistently working to prolong the lives of patients fighting MBC.
Ibrance is included in the majority of the provincial cancer drug formularies, but a number of eligibility criteria were imposed that drastically reduced the population of MBC patients that Ibrance would be funded for.
With this current protocol, the only patients who Ibrance is covered for is the newly diagnosed who also meet the eligibility requirements of being Er+ Pr+ HER2-, post-menopausal without ovarian suppression and who have yet to attempt any forms of treatments.
Help Chasing Hope MBC reach 15,000 signatures, to help more patients with metastatic breast cancer get the treatment they need and deserve.